uniQure (QURE) Total Non-Current Liabilities (2015 - 2026)
uniQure (QURE) recorded quarterly Total Non-Current Liabilities of $570.2 million in Q1 2026, up 1.26% quarter-over-quarter from $563.1 million in Q4 2025, and up 6.49% on a YoY basis from $535.4 million in Q1 2025.
uniQure (QURE) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
uniQure's Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $570.2 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 6.49% year-over-year to $570.2 million; the TTM figure through Mar 2026 stood at $570.2 million (up 6.49% YoY), while the FY2025 annual figure was $563.1 million, up 7.62% from the prior year.
- Total Non-Current Liabilities was $570.2 million for Q1 2026 at uniQure, up from $563.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $570.2 million in Q1 2026 to a low of $151.9 million in Q1 2023.
- Historically, Total Non-Current Liabilities has averaged $431.0 million across 5 years, with a median of $534.2 million in 2023.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities retreated 13.36% in 2022, then soared 268.55% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $153.0 million in 2022, then soared by 259.62% to $550.3 million in 2023, then fell by 4.93% to $523.2 million in 2024, then advanced by 7.62% to $563.1 million in 2025, then gained by 1.26% to $570.2 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $570.2 million (Q1 2026), $563.1 million (Q4 2025), and $559.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | uniQure | 2.88 Bn | 2.88 Bn | 3.34 Mn | 570.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 570.17 Mn |
| Dec 31, 2025 | 563.09 Mn |
| Sep 30, 2025 | 559.00 Mn |
| Jun 30, 2025 | 547.96 Mn |
| Mar 31, 2025 | 535.41 Mn |
| Dec 31, 2024 | 523.24 Mn |
| Sep 30, 2024 | 518.71 Mn |
| Jun 30, 2024 | 553.27 Mn |
| Mar 31, 2024 | 559.82 Mn |
| Dec 31, 2023 | 550.34 Mn |
| Sep 30, 2023 | 534.16 Mn |
| Jun 30, 2023 | 521.09 Mn |
| Mar 31, 2023 | 151.90 Mn |
| Dec 31, 2022 | 153.04 Mn |
| Sep 30, 2022 | 153.09 Mn |
| Jun 30, 2022 | 166.46 Mn |
| Mar 31, 2022 | 166.45 Mn |
| Dec 31, 2021 | 176.64 Mn |
| Sep 30, 2021 | 141.95 Mn |
| Jun 30, 2021 | 104.56 Mn |